Acknowledgements We would like to express our thanks to our fellow PEVIA collaborators for their great work, as well as the Innovative Medicines Initiative, the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations for their support, and for allowing this project to happen.
We also thank the Secretariat for Education, Research and Innovation (SERI) in Bern, Switzerland, which provided funding to the research group of Prof. François Spertini at the Cantonal University Hospital of Vaud and also supported the work at ExcellGene.